Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
This story comes from CNBC's feed; the full article and all rights belong to the source.
Comments (0)
No comments yet. Be the first to comment.
Sign in to write a comment.